Experimental suppression of FKBP51—genetically or pharmacologically—enhances the levels of autophagic markers LC3 and SQSTM1/p62 and reduces mHTT accumulation in HD NSCs and mouse models (Bailus et al., 2021). Here, FKBP5 is linked to Huntington disease.